VENTX Human shRNA Plasmid Kit (Locus ID 27287)
VENTX - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector
|Product Name||VENTX Human shRNA Plasmid Kit (Locus ID 27287)|
|Synonyms||HPX42B; NA88A; VENTX2|
|Kit Components||VENTX - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 27287). 5µg purified plasmid DNA per constructNon-effective 29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.|
|Summary||This gene encodes a member of the Vent family of homeodomain proteins. The encoded protein may function as a transcriptional repressor and be involved in mesodermal patterning and hemopoietic stem cell maintenance. Multiple pseudogenes exist for this gene. A transcribed pseudogene located on chromosome X may lead to antigen production in certain melanomas. [provided by RefSeq, Jul 2008].|
|shRNA Design||These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, align it with our published shRNA design sequences. If these do not align, please utilize our custom shRNA service|
|Performance Guaranteed||OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at email@example.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).
|The use of this RNAi has been cited in the following citations:|
VentX, a Novel Lymphoid-Enhancing Factor/T-Cell Factor–Associated Transcription Repressor, Is a Putative Tumor Suppressor
,Hong Gao, Yi Le, Xiaoming Wu, Leslie E. Silberstein, Roger W. Giese, and Zhenglun Zhu,
Cancer Res., Jan 2010; 70: 202 - 211